Researchers in Spain found that guiding IV fluid and vasoactive drug administration with esophageal doppler monitoring significantly reduced complications after major surgery, News Medical reports.

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Deltex Medical Group plc (LON:DEMG), that sends out a ...

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Deltex Medical Group plc (LON:DEMG) shareholders should be happy to see the ...

Deltex Medical Group has seen an increase in shareholder Michael Stubbs’ stake, now holding 6.45% of the company, following a recent purchase of shares. This development comes as Deltex continues to ...

Multicenter randomized controlled trial results published; fewer complications translate to better patient outcomes and lower healthcare costs, as evidenced by NICE guidelines Deltex Medical, the ...

'Buy' and 'sell' recommendations from company analysts often catch the attention of investors - but it's worth remembering that city experts can get things wrong. So rather than relying on just one ...

GREENVILLE, S.C.--(BUSINESS WIRE)-- A less invasive technology to optimize patient care during surgeries and in intensive care settings has received another major international endorsement for ...

Deltex Medical Group plc (DTXMF) stock price is 0.10 and Deltex Medical Group plc (DTXMF) 10-day simple moving average is 0.10. Deltex Medical Group plc (DTXMF) stock price is 0.10 and Deltex Medical ...

WASHINGTON, May 22 (Reuters) - The U.S. Medicare insurance program said on Tuesday it will now cover a procedure to monitor the heart's blood output in certain settings, following a request by British ...

@JohnCFierce: Ariad shares shot up 36 percent on sarcoma data. Three weeks isn't much time, but deadly cancers have their own metric for success. | Follow @JohnCFierce > Preparing for future flu ...

One of the best performers of the day is Aim-listed Deltex Medical after further approval of its blood flow monitor, which analysts say could save the NHS more than £1bn a year. The National Institute ...